JP2017528129A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528129A5
JP2017528129A5 JP2017510624A JP2017510624A JP2017528129A5 JP 2017528129 A5 JP2017528129 A5 JP 2017528129A5 JP 2017510624 A JP2017510624 A JP 2017510624A JP 2017510624 A JP2017510624 A JP 2017510624A JP 2017528129 A5 JP2017528129 A5 JP 2017528129A5
Authority
JP
Japan
Prior art keywords
nmi
ifp35
seq
activity
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017510624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528129A (ja
JP6968696B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/000602 external-priority patent/WO2016026258A1/en
Publication of JP2017528129A publication Critical patent/JP2017528129A/ja
Publication of JP2017528129A5 publication Critical patent/JP2017528129A5/ja
Application granted granted Critical
Publication of JP6968696B2 publication Critical patent/JP6968696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017510624A 2014-08-22 2015-08-21 異常なレベル及び/又は活性のifp35ファミリーのタンパク質に関連する疾患又は障害を治療及び/又は予防するための方法及び組成物 Active JP6968696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410418773.1 2014-08-22
CN201410418773 2014-08-22
PCT/CN2015/000602 WO2016026258A1 (en) 2014-08-22 2015-08-21 Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins

Publications (3)

Publication Number Publication Date
JP2017528129A JP2017528129A (ja) 2017-09-28
JP2017528129A5 true JP2017528129A5 (https=) 2018-10-04
JP6968696B2 JP6968696B2 (ja) 2021-11-17

Family

ID=55350147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510624A Active JP6968696B2 (ja) 2014-08-22 2015-08-21 異常なレベル及び/又は活性のifp35ファミリーのタンパク質に関連する疾患又は障害を治療及び/又は予防するための方法及び組成物

Country Status (5)

Country Link
US (4) US11466061B2 (https=)
EP (1) EP3182990A4 (https=)
JP (1) JP6968696B2 (https=)
CN (3) CN114796497A (https=)
WO (1) WO2016026258A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016026258A1 (en) 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN118767136A (zh) * 2019-04-01 2024-10-15 广州恩迈生物科技有限公司 慢性炎症的诊断和治疗
CN110669765B (zh) * 2019-11-04 2022-11-01 中国科学院水生生物研究所 鳜干扰素诱导蛋白启动子和应用
CN113234153B (zh) * 2021-04-07 2022-12-20 中山大学 一批识别ifp35家族蛋白的单克隆抗体及其在免疫识别等方面的应用
CN118667938A (zh) * 2021-07-09 2024-09-20 广州恩迈生物科技有限公司 Ifp35和/或nmi在诊治疾病中的应用
CN116239685A (zh) * 2023-02-24 2023-06-09 中山大学·深圳 一种识别ifp35蛋白的抗体及其应用
EP4682166A1 (en) * 2023-04-10 2026-01-21 Guangzhou Enmai Biotechnology Co., Ltd Anti-nmi monoclonal antibody or antigen-binding fragment thereof, and use thereof
CN120536560A (zh) * 2024-02-19 2025-08-26 中山大学·深圳 Ifp35家族蛋白在诊断脓毒症或其相关疾病中的应用
CN120842381A (zh) * 2025-07-22 2025-10-28 中山大学 一种识别nmi蛋白的单克隆抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0921192A1 (en) 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
EP1807540A4 (en) * 2004-11-05 2008-12-10 Us Gov Sec Navy DIAGNOSIS AND PROGNOSIS OF CLINICAL PHENOTYPES OF INFECTION DISEASES AND OTHER PHYSIOLOGICAL CONDITIONS USING GENE EXPRESSION OF A HOSTS AS BIOMARKERS IN THE BLOOD
RU2008117085A (ru) * 2005-10-03 2009-11-10 Новартис АГ (CH) Консервативный мембранный активатор кальциневрина (смас), новый терапевтический белок и мишень
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
WO2007127756A2 (en) * 2006-04-24 2007-11-08 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
NZ573052A (en) * 2006-04-26 2012-03-30 Vertex Pharma Hepatitis c virus infection biomarkers
KR101326367B1 (ko) * 2006-07-03 2013-11-11 가톨릭대학교 산학협력단 항암제 저항성의 진단 방법 및 진단 키트
AU2007286915B2 (en) 2006-08-11 2014-05-15 Baylor Research Institute Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
EP2170311A4 (en) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
WO2016026258A1 (en) 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN118767136A (zh) 2019-04-01 2024-10-15 广州恩迈生物科技有限公司 慢性炎症的诊断和治疗

Similar Documents

Publication Publication Date Title
JP2017528129A5 (https=)
JP2016020389A5 (https=)
JP2013165711A5 (https=)
JP2014524746A5 (https=)
JP2019511222A5 (https=)
RU2015144105A (ru) Антитела к гепсидину и их применения
EP4039274A1 (en) Anti-tim-3 antibodies and uses thereof
JP2016513664A5 (https=)
JP2018531914A (ja) CD155/TIGIT経路およびTGF−βのアンタゴニストを介してがんを処置するための組成物および方法
JP2021517566A (ja) 汎発性膿疱性乾癬の処置のための抗il−36r抗体の使用
RU2018107047A (ru) Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
JP2013539468A5 (https=)
JP2016520520A5 (https=)
JP2015506944A5 (https=)
JP2015506945A5 (https=)
JP2016538297A5 (https=)
RU2663694C2 (ru) Лечение злокачественных новообразований на основе стратификации по caix
JP2019519475A (ja) ヒト化抗clever−1抗体およびその使用
CN108473582A (zh) 用于治疗纤维化和/或纤维化病症的抗-αV整合素抗体
JP2023115014A (ja) 線維症および/または線維性疾患の治療のための抗α-vインテグリン抗体
KR20200068746A (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
JP2021502344A (ja) 腫瘍を処置する方法
JP2018509423A5 (https=)
RU2020115161A (ru) Днк моноклональных антител против ctla-4 для лечения и профилактики рака
JP2021525512A (ja) 抗aベータ抗体及びその使用